// App-Quantinova.ai

EP1039 : Monthly pasireotide provides clinical benefit over 12 months in patients with Cushing's disease

Researchers

Presenter

  • Rosario Pivonello

Principal Investigators

  • Marcello Bronstein

  • Jochen Schopohl

  • Tuncay Delibasi

  • Ariel Barkan

  • Nori Suzaki

  • Libuse Tauchmanova

  • Pritam Gupta

  • Stefan Petersenn

  • Andr Lacroix

Medical Centers

  • Universita Federico II di Napoli, Napoli, Italy

  • University of Sao Paulo Medical School, Sao Paulo, Brazil

  • Medizinische Klinik IV, University of Munich, Munich, Germany

  • Hacettepe University, Ankara, Turkey

  • Nagoya Medical Center, National Hospital Organization, Nagoya, Japan

  • Novartis AG, Basel, Switzerland

  • Novartis Healthcare Pvt. Ltd, Hyderabad, India

  • ENDOC Center for Endocrine Tumors, Hamburg, Germany

  • Centre Hospitalier de LUniversite de Montreal (CHUM), Montreal, QC, Canada

Locations

  • Italy

  • Brazil

  • Germany

  • Turkey

  • United States

  • Japan

  • Switzerland

  • India

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Pasireotide

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved